From: Recurrent glomerulonephritis following renal transplantation and impact on graft survival
IgA | MCGN | MN | FSGS | Other GN | Total GN | Non-GN | P value | |
---|---|---|---|---|---|---|---|---|
Number (% of Total GN) | 2393 (33.07%) | 348 (4.81%) | 309 (4.27%) | 975 (13.47%) | 3211 (44.38%) | 7236 | 8787 | |
Age (years) Median (IQR) | 45 (36–54) | 40 (29–51) | 49 (38–58) | 43 (32–55) | 44 (32–55) | 44 (33–54) | 47 (33–56) | < 0.001 |
Male gender | 1815 (75.8%) | 200 (57.5%) | 235 (76.1%) | 651 (66.8%) | 1891 (58.9%) | 4792 (66.2%) | 4967 (56.5%) | < 0.001 |
Caucasian Ethnicity (%) | 1889 (78.9%) | 286 (82.1%) | 274 (88.7%) | 839 (86.1%) | 2584 (80.5%) | 5872 (81.1%) | 7667 (87.2%) | < 0.001 |
Graft Number | < 0.001 | |||||||
Primary graft | 2162 (90.35%) | 288 (82.76%) | 278 (89.97%) | 861 (88.61%) | 2886 (89.88%) | 6475 (89.5%) | 8096 (92.14%) | |
Secondary | 215 (8.98%) | 55 (15.80%) | 30 (9.71%) | 98 (10.05%) | 288 (8.97%) | 686 (9.5%) | 629 (7.16%) | |
Subsequent | 16 (0.67%) | 5 (1.44%) | 1 (0.32%) | 16 (1.64%) | 37 (1.15%) | 75 (1%) | 62 (0.71%) | |
Donor Category | < 0.001 | |||||||
Deceased donor | 1552 (64.9%) | 260 (74.7%) | 210 (68.0%) | 671 (68.8%) | 2263 (70.5%) | 4956 (68.5%) | 6201 (70.6%) | |
Live related donor | 557 (23.2%) | 57 (16.4%) | 71 (23.0%) | 207 (21.2%) | 684 (21.3%) | 1576 (21.8%) | 1686 (19.2%) | |
Live unrelated donor | 284 (11.9%) | 31 (8.9%) | 28 (9.1%) | 97 (9.9%) | 264 (8.2%) | 704 (9.7%) | 900 (10.2%) | |
DM as comorbidity (% of Total GN) | 73 (3.1%) | 18 (5.2%) | 15 (4.9%) | 57 (5.8%) | 103 (3.2%) | 266 (3.7%) | 1938 (22.1%) | < 0.001 |
Peak panel reactive antibodies (%) Median (IQR) | 3 (0–14) | 5 (0–29) | 3 (0–16) | 3 (0–21) | 4 (0–25) | 3 (0–20) | 3 (0–16) | < 0.001 |
Total ischaemic time in hours (Median (IQR)) | 10 (3–15) | 13 (4–19) | 11 (3–16) | 11 (3–16) | 12 (4–17) | 11 (3–16) | 11 (4–16) | < 0.001 |
Zero HLA mismatches n(%) | 179 (7.5%) | 25 (7.2%) | 21 (6.8%) | 63 (6.5%) | 245 (7.7%) | 534 (7.4%) | 597 (6.8%) | 0.55 |